Michallet, A. Et Al. 2018. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study. HAEMATOLOGICA , vol.103, no.4 , 698-706.

Michallet, A., Aktan, M., Hiddemann, W., Ilhan, O., Johansson, P., Laribi, K., ... Meddeb, B.(2018). Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study. HAEMATOLOGICA , vol.103, no.4, 698-706.

Michallet, Anne-Sophie Et Al. "Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study," HAEMATOLOGICA , vol.103, no.4, 698-706, 2018

Michallet, Anne-Sophie Et Al. "Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study." HAEMATOLOGICA , vol.103, no.4, pp.698-706, 2018

Michallet, A. Et Al. (2018) . "Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study." HAEMATOLOGICA , vol.103, no.4, pp.698-706.

@article{article, author={Anne-Sophie Michallet Et Al. }, title={Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study}, journal={HAEMATOLOGICA}, year=2018, pages={698-706} }